Literature DB >> 19632179

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

Ravindra Majeti1, Mark P Chao, Ash A Alizadeh, Wendy W Pang, Siddhartha Jaiswal, Kenneth D Gibbs, Nico van Rooijen, Irving L Weissman.   

Abstract

Acute myeloid leukemia (AML) is organized as a cellular hierarchy initiated and maintained by a subset of self-renewing leukemia stem cells (LSC). We hypothesized that increased CD47 expression on human AML LSC contributes to pathogenesis by inhibiting their phagocytosis through the interaction of CD47 with an inhibitory receptor on phagocytes. We found that CD47 was more highly expressed on AML LSC than their normal counterparts, and that increased CD47 expression predicted worse overall survival in three independent cohorts of adult AML patients. Furthermore, blocking monoclonal antibodies directed against CD47 preferentially enabled phagocytosis of AML LSC and inhibited their engraftment in vivo. Finally, treatment of human AML LSC-engrafted mice with anti-CD47 antibody depleted AML and targeted AML LSC. In summary, increased CD47 expression is an independent, poor prognostic factor that can be targeted on human AML stem cells with blocking monoclonal antibodies capable of enabling phagocytosis of LSC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632179      PMCID: PMC2726837          DOI: 10.1016/j.cell.2009.05.045

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  44 in total

Review 1.  Acute myeloid leukemia.

Authors:  B Löwenberg; J R Downing; A Burnett
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

Review 2.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 3.  Cancer stem cells.

Authors:  Craig T Jordan; Monica L Guzman; Mark Noble
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

4.  Species- and cell type-specific interactions between CD47 and human SIRPalpha.

Authors:  Shyamsundar Subramanian; Ranganath Parthasarathy; Shamik Sen; Eric T Boder; Dennis E Discher
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 5.  Cancer stem cells: lessons from leukemia.

Authors:  Jean C Y Wang; John E Dick
Journal:  Trends Cell Biol       Date:  2005-09       Impact factor: 20.808

6.  Stem cell research: paths to cancer therapies and regenerative medicine.

Authors:  Irving Weissman
Journal:  JAMA       Date:  2005-09-21       Impact factor: 56.272

7.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells.

Authors:  Liqing Jin; Kristin J Hope; Qiongli Zhai; Florence Smadja-Joffe; John E Dick
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

Review 8.  The SIRP family of receptors and immune regulation.

Authors:  A Neil Barclay; Marion H Brown
Journal:  Nat Rev Immunol       Date:  2006-06       Impact factor: 53.106

Review 9.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

10.  Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system.

Authors:  Hideki Okazawa; Sei-ichiro Motegi; Naoko Ohyama; Hiroshi Ohnishi; Takeshi Tomizawa; Yoriaki Kaneko; Per-Arne Oldenborg; Osamu Ishikawa; Takashi Matozaki
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

View more
  602 in total

Review 1.  Macrophages as mediators of tumor immunosurveillance.

Authors:  Siddhartha Jaiswal; Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Trends Immunol       Date:  2010-05-07       Impact factor: 16.687

Review 2.  Molecular pathways to CML stem cells.

Authors:  Kristen N Rice; Catriona H M Jamieson
Journal:  Int J Hematol       Date:  2010-06-10       Impact factor: 2.490

Review 3.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

Review 4.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

5.  CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.

Authors:  Masayuki Iwasaki; Michaela Liedtke; Andrew J Gentles; Michael L Cleary
Journal:  Cell Stem Cell       Date:  2015-09-18       Impact factor: 24.633

6.  Characterization of cluster of differentiation 47 expression and its potential as a therapeutic target in esophageal squamous cell cancer.

Authors:  Chun-Lin Zhao; Shuang Yu; Shu-Hui Wang; Shi-Gang Li; Zhi-Ju Wang; Sheng-Na Han
Journal:  Oncol Lett       Date:  2017-11-20       Impact factor: 2.967

7.  Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells.

Authors:  Zhen Bian; Lei Shi; Ya-Lan Guo; Zhiyuan Lv; Cong Tang; Shuo Niu; Alexandra Tremblay; Mahathi Venkataramani; Courtney Culpepper; Limin Li; Zhen Zhou; Ahmed Mansour; Yongliang Zhang; Andrew Gewirtz; Koby Kidder; Ke Zen; Yuan Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-30       Impact factor: 11.205

Review 8.  Macrophages: gatekeepers of tissue integrity.

Authors:  Yonit Lavin; Miriam Merad
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

9.  Universal monitoring of minimal residual disease in acute myeloid leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Sheila Shurtleff; Allen Eng-Juh Yeoh; Wee Joo Chng; Siew Peng Chen; Jeffrey E Rubnitz; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  JCI Insight       Date:  2018-05-03

10.  Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.

Authors:  Yuki Kagiyama; Jiro Kitaura; Katsuhiro Togami; Tomoyuki Uchida; Daichi Inoue; Toshihiro Matsukawa; Kumi Izawa; Kimihito C Kawabata; Yukiko Komeno; Toshihiko Oki; Fumio Nakahara; Katsuaki Sato; Hiroyuki Aburatani; Toshio Kitamura
Journal:  Int J Hematol       Date:  2012-10-25       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.